Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study - PubMed (original) (raw)
Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study
I Magnusson et al. J Clin Invest. 1992 Oct.
Abstract
To quantitate hepatic glycogenolysis, liver glycogen concentration was measured with 13C nuclear magnetic resonance spectroscopy in seven type II diabetic and five control subjects during 23 h of fasting. Net hepatic glycogenolysis was calculated by multiplying the rate of glycogen breakdown by the liver volume, determined from magnetic resonance images. Gluconeogenesis was calculated by subtracting the rate of hepatic glycogenolysis from the whole body glucose production rate, measured using [6-3H]glucose. Liver glycogen concentration 4 h after a meal was lower in the diabetics than in the controls; 131 +/- 20 versus 282 +/- 60 mmol/liter liver (P < 0.05). Net hepatic glycogenolysis was decreased in the diabetics, 1.3 +/- 0.2 as compared to 2.8 +/- 0.7 mumol/(kg body wt x min) in the controls (P < 0.05). Whole body glucose production was increased in the diabetics as compared to the controls, 11.1 +/- 0.6 versus 8.9 +/- 0.5 mumol/(kg body wt x min) (P < 0.05). Gluconeogenesis was consequently increased in the diabetics, 9.8 +/- 0.7 as compared to 6.1 +/- 0.5 mumol/(kg body wt x min) in the controls (P < 0.01), and accounted for 88 +/- 2% of total glucose production as compared with 70 +/- 6% in the controls (P < 0.05).
In conclusion: increased gluconeogenesis is responsible for the increased whole body glucose production in type II diabetes mellitus after an overnight fast.
Similar articles
- Contribution of net hepatic glycogenolysis to glucose production during the early postprandial period.
Petersen KF, Price T, Cline GW, Rothman DL, Shulman GI. Petersen KF, et al. Am J Physiol. 1996 Jan;270(1 Pt 1):E186-91. doi: 10.1152/ajpendo.1996.270.1.E186. Am J Physiol. 1996. PMID: 8772491 - Contributions of net hepatic glycogenolysis and gluconeogenesis to glucose production in cirrhosis.
Petersen KF, Krssak M, Navarro V, Chandramouli V, Hundal R, Schumann WC, Landau BR, Shulman GI. Petersen KF, et al. Am J Physiol. 1999 Mar;276(3):E529-35. doi: 10.1152/ajpendo.1999.276.3.E529. Am J Physiol. 1999. PMID: 10070020 - Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR.
Rothman DL, Magnusson I, Katz LD, Shulman RG, Shulman GI. Rothman DL, et al. Science. 1991 Oct 25;254(5031):573-6. doi: 10.1126/science.1948033. Science. 1991. PMID: 1948033 - Nuclear magnetic resonance studies of hepatic glucose metabolism in humans.
Roden M, Petersen KF, Shulman GI. Roden M, et al. Recent Prog Horm Res. 2001;56:219-37. doi: 10.1210/rp.56.1.219. Recent Prog Horm Res. 2001. PMID: 11237214 Review.
Cited by
- Precision-cut liver slices as an ex vivo model to assess impaired hepatic glucose production.
Kiyuna LA, Krishnamurthy KA, Homan EB, Langelaar-Makkinje M, Gerding A, Bos T, Oosterhuis D, Overduin RJ, Schreuder AB, de Meijer VE, Olinga P, Derks TGJ, van Eunen K, Bakker BM, Oosterveer MH. Kiyuna LA, et al. Commun Biol. 2024 Nov 9;7(1):1479. doi: 10.1038/s42003-024-07070-z. Commun Biol. 2024. PMID: 39521914 Free PMC article. - BCKDH kinase promotes hepatic gluconeogenesis independent of BCKDHA.
Zhou F, Sheng C, Ma X, Li T, Ming X, Wang S, Tan J, Yang Y, Sun H, Lu J, Liu J, Deng R, Wang X, Zhou L. Zhou F, et al. Cell Death Dis. 2024 Oct 10;15(10):736. doi: 10.1038/s41419-024-07071-0. Cell Death Dis. 2024. PMID: 39389936 Free PMC article. - Small molecules targeting selective PCK1 and PGC-1α lysine acetylation cause anti-diabetic action through increased lactate oxidation.
Mutlu B, Sharabi K, Sohn JH, Yuan B, Latorre-Muro P, Qin X, Yook JS, Lin H, Yu D, Camporez JPG, Kajimura S, Shulman GI, Hui S, Kamenecka TM, Griffin PR, Puigserver P. Mutlu B, et al. Cell Chem Biol. 2024 Oct 17;31(10):1772-1786.e5. doi: 10.1016/j.chembiol.2024.09.001. Epub 2024 Sep 27. Cell Chem Biol. 2024. PMID: 39341205 - Metabolomics combined with intestinal microbiota reveals the mechanism of compound Qilian tablets against diabetic retinopathy.
Jia J, Liu B, Wang X, Ji F, Wen F, Xu H, Ding T. Jia J, et al. Front Microbiol. 2024 Aug 16;15:1453436. doi: 10.3389/fmicb.2024.1453436. eCollection 2024. Front Microbiol. 2024. PMID: 39220039 Free PMC article. - CPS1 augments hepatic glucagon response through CaMKII/FOXO1 pathway.
Sun XM, Wu X, Wei MG, Zhu LZ, Wu WH, Zhou XY, Qi LW, Liu Q. Sun XM, et al. Front Pharmacol. 2024 Aug 13;15:1437738. doi: 10.3389/fphar.2024.1437738. eCollection 2024. Front Pharmacol. 2024. PMID: 39193349 Free PMC article.
References
- Scand J Clin Lab Invest. 1973 Dec;32(4):317-23 - PubMed
- J Clin Invest. 1984 Oct;74(4):1238-46 - PubMed
- Diabetes. 1975 Aug;24(8):730-4 - PubMed
- Science. 1991 Oct 25;254(5031):573-6 - PubMed
- J Clin Invest. 1990 Dec;86(6):2038-45 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical